Spruce Biosciences Presented Results From Phase 2 POWER Study Of Tildacerfont For Polycystic Ovary Syndrome At The 2024 Annual Meeting Of The Endocrine Society

Benzinga · 06/03 11:11
  • Significant Reduction in Dehydroepiandrosterone Sulfate (DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline
  • Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed
  • Tildacerfont was Well-Tolerated with No Safety Signals